PAR 2.13% 23.0¢ paradigm biopharmaceuticals limited..

Chart, page-2501

  1. 1,052 Posts.
    lightbulb Created with Sketch. 531
    The reason the share price is where it is
    1. The market for PAR shares is the Australian market and what the Australian market knows or likes is mining, banks, property and betting on unicorns (and some others).
    2. A lot of people bought in at higher prices and were hoping for takeoff on the IND announcement.
    3. Those people hung on for the six+ months delay.
    4. They now realize the readout for 008 is still just a first step and it is at least as far away as indicated earlier..
    5. They realize now that there is not enough money to complete the trials without a CR or a deal.
    6. Other investments that fit their reasons for investing in PAR now look more attractive in the short term (to them), think lithium, fintech and other unicorns, supply chain turnaround.
    7. They are putting their money somewhere else, ie selling.
    8. The Australian market is small in relation to the US market.
    9. Patience v impatience

    If you want to see the price rise
    a) wait till they have sold out (it doesn't happen overnight, it depends on waning patience)
    b) tell PAR BoD you want to see PAR listed as Depository Receipts in the US.
    Check out the share price of BRN since Nov 3rd when they began to participate in Depository Receipts and compare that to PAR (not recommending BRN as such), just the effect of the most recent co that has done that.

    The US market is >30x ours. That is a lot of new potential buyers.

    If you do not take action on (b) ask yourself why as the share price slumbers.
    IMO. DYOR. here...
    investopedia.com/terms/d/depositaryreceipt.asp

    fidelity.com/learning-center/investment-products/stocks/understanding-american-depositary-receipts
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.